[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331302-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-331302-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","burden-of-female-breast-and-five-gynecological-cancers-in-china-and-worldwide","Burden of Female Breast and Five Gynecological Cancers in China and Worldwide","","Female breast and five gynecological cancers remain a major health burden in China and globally. Using the latest GLOBOCAN 2022 estimates, the study characterizes disease-burden profiles and compares age-specific incidence and mortality rates between China and other countries. It analyzes the share of total cancer cases and deaths attributable to these tumors versus other cancer types, and correlates ASIR/ASMR with the Human Development Index while visualizing age-specific trends across representative income-level countries.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/burden-of-female-breast-and-five-gynecological-cancers-in-china-and-worldwide/331302/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/burden-of-female-breast-and-five-gynecological-cancers-in-china-and-worldwide/331302.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of the study on female breast and five gynecological cancers?","Question",{"text":63,"@type":64},"To describe profiles of disease burden and compare age-specific incidence rates between China and other countries using GLOBOCAN 2022 estimates.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which data source is used to estimate incidence and mortality?",{"text":68,"@type":64},"The study extracts the latest incidence and mortality estimates from the GLOBOCAN 2022 database.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationships are evaluated between cancer rates and development level?",{"text":72,"@type":64},"Correlation analysis assesses how age-standardized incidence rate (ASIR) or age-standardized mortality rate (ASMR) relate to the Human Development Index (HDI).",{"name":74,"@type":61,"acceptedAnswer":75},"What prevention strategy is recommended based on the findings?",{"text":76,"@type":64},"Implement comprehensive prevention strategies targeted to increasing trends among younger individuals and to reduce regional disparities.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},331302,1790095898,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":116,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Burden of female breast and five gynecological cancers in China and worldwide  \nNuopei Tan1, You Wu2, Bin Li2, Wanqing Chen1  \n1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;  \n2Department of Gynecology Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.  \nAbstract  \nBackground: Female breast and five gynecological cancers remain substantial burden in China and worldwide. GLOBOCAN 2022 has recently updated the estimates of cancer burden. This study aims to depict the profiles of disease burden and to compare the age-specific rates of female breast and five gynecological cancers in China with those in other countries.  \nMethods: The latest estimates of incidence and mortality of female breast and five gynecological cancers from various regions and countries were extracted from the GLOBOCAN 2022 database. We compared the proportion of total cases or deaths for cancers affecting female breast and five gynecological cancers and other tumor types in China and globally. Correlation analysis was conducted to evaluate the relationship between age-standardized incidence rate (ASIR) or age-standardized mortality rate (ASMR) and the Human Development Index (HDI). Additionally, age-specific rate curves were plotted for ten exemplary countries with different income levels.  \nResults: Female breast and five gynecological cancers in China accounted for 30.2% of all newly diagnosed cancer cases. Breast cancer and cervical cancer are the most commonly diagnosed, with nearly 507,000 new cases, representing 23.48% of the new cases. The incidence rates of breast, uterine corpus, ovarian, and vulvar cancers were positively associated with HDI tiers. Chinese women aged 50–54 years are experiencing high incidence rates of breast, cervix uteri, corpus uteri, and ovarian cancers. Conclusions: Female breast and five gynecological cancers continue to be a significant health concern for women in China and worldwide. It is crucial to implement comprehensive prevention strategies tailored to address the increasing trend among younger individuals and reduce regional disparities.  \nKeywords: Cancer incidence; Cancer mortality; China; GLOBOCAN; Worldwide; Female organ; Breast cancer; Ovarian cancer  \nIntroduction  \nFemale breast and five gynecological cancers have emerged as crucial contributors to disease and financial burden worldwide, owing to their insidious onset, poor prognosis, and high risk of recurrence after treatments. [1–3] According to the 2022 World Health Organization (WHO) estimates, six major cancers in female organs were assessed, including female breast, vulva, vagina, cervix uteri, corpus uteri, and ovary. These cancers accounted for nearly 3.6 million new cases and 1.2 million deaths globally, with breast cancer responsible for nearly half of each number and ranking first among all cancers in women. Cervical cancer is the fourth most frequently diagnosed malignancy and the third leading cause of cancer death, whereas corpus uteri and ovary cancers within the top 10 in incidence and mortality rate. [1] Although vaginal and vulvar carcinomas  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code: | Website:\u003Cbr>[www.cmj.org](www.cmj.org) |\n|  | DOI:\u003Cbr>10.1097/CM9.0000000000003293 |\n\nare rare entities, they are increasingly being observed in younger women due to the rise in persistent high-risk human papillomavirus (HPV) infections. [4,5] Extensive geographic disparities exist in the burden of cancers in female breast and gynecological organs. Approximately 78% of new cases and over 50% of cancer deaths in these organs were in high and upper middle-income countries,[1] whereas over 80% of women diagnosed and 90% of deaths from cervica","cbCaiutoIpxOJKq1","https://ap.wps.com/l/cbCaiutoIpxOJKq1","pdf",1329000,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the purpose of the study on female breast and five gynecological cancers?\",\"answer\":\"To describe profiles of disease burden and compare age-specific incidence rates between China and other countries using GLOBOCAN 2022 estimates.\"},{\"question\":\"Which data source is used to estimate incidence and mortality?\",\"answer\":\"The study extracts the latest incidence and mortality estimates from the GLOBOCAN 2022 database.\"},{\"question\":\"What relationships are evaluated between cancer rates and development level?\",\"answer\":\"Correlation analysis assesses how age-standardized incidence rate (ASIR) or age-standardized mortality rate (ASMR) relate to the Human Development Index (HDI).\"},{\"question\":\"What prevention strategy is recommended based on the findings?\",\"answer\":\"Implement comprehensive prevention strategies targeted to increasing trends among younger individuals and to reduce regional disparities.\"}]","Burden of Female Breast and Five Gynecological Cancers in China and Worldwide | PDF",1789992587]